Make a Gift
A dedicated donation supporting ovarian and related gynecologic cancers research is a perfect way to honor or remember your loved one.
Read more about Make a Gift Accelerate our progress toward a cure with a dedicated donation
Donate in Honor of Someone You Love
Honor a Loved One
Every day, patients and families around the world are impacted by ovarian cancer. And every day, OCRA-funded scientists are working on the most promising research to create new, more effective treatments, achieve desperately needed breakthroughs, and get closer to a cure. Honor or remember a loved one by giving a dedicated donation.
Create or Donate to a Tribute Page
Transform devotion into action by fundraising in honor or in memory of someone special or donating to an existing page.
Read more about Create or Donate to a Tribute Page Pay tribute
Share Your Photos and Story
Spread the word and raise awareness by sharing your or your loved one’s experience with ovarian and related gynecologic cancers.
Related Topics
OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued